Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion.

We present a cohort of 41 patients with osimertinib resistance biopsies, including two with an acquired CCDC6-RET fusion. While RET fusions have been identified in resistant EGFR-mutant NSCLC, their role in acquired resistance to EGFR inhibitors is not well described. To assess the biological implic...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancer Discov
Главные авторы: Piotrowska, Zofia, Isozaki, Hideko, Lennerz, Jochen K., Gainor, Justin F., Lennes, Inga T., Zhu, Viola W., Marcoux, Nicolas, Banwait, Mandeep K., Digumarthy, Subba R., Su, Wenjia, Yoda, Satoshi, Riley, Amanda K., Nangia, Varuna, Lin, Jessica J., Nagy, Rebecca J., Lanman, Richard B., Dias-Santagata, Dora, Mino-Kenudson, Mari, Iafrate, A. John, Heist, Rebecca S., Shaw, Alice T., Evans, Erica K., Clifford, Corinne, Ou, Sai-Hong I., Wolf, Beni, Hata, Aaron N., Sequist, Lecia V.
Формат: Artigo
Язык:Inglês
Опубликовано: 2018
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6279502/
https://ncbi.nlm.nih.gov/pubmed/30257958
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-18-1022
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы